{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T15:45:30Z","timestamp":1770565530805,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,7]]},"DOI":"10.7759\/cureus.103163","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:49:57Z","timestamp":1770479397000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Tofacitinib Compared to Cyclophosphamide in Early Diffuse Cutaneous Systemic Sclerosis: A Randomized Controlled Trial"],"prefix":"10.7759","author":[{"given":"Nabil","family":"Amin Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariful","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abu","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Jamil Abdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Atiqul","family":"Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes MD","year":"2003","unstructured":"Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003, 48:2246-55. 10.1002\/art.11073","journal-title":"Arthritis Rheum"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai M","year":"2012","unstructured":"Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012, 51:1017-26. 10.1093\/rheumatology\/ker269","journal-title":"Rheumatology (Oxford)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort","volume":"78","author":"Wu W","year":"2019","unstructured":"Wu W, Jordan S, Graf N, et al.. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis. 2019, 78:648-56. 10.1136\/annrheumdis-2018-213455","journal-title":"Ann Rheum Dis"},{"key":"ref4","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements P","year":"1995","unstructured":"Clements P, Lachenbruch P, Siebold J, et al.. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995, 22:1281-5.","journal-title":"J Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/2397198319865367","article-title":"The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib","volume":"5","author":"Wang W","year":"2020","unstructured":"Wang W, Bhattacharyya S, Marangoni RG, et al.. The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. J Scleroderma Relat Disord. 2020, 5:40-50. 10.1177\/2397198319865367","journal-title":"J Scleroderma Relat Disord"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.24688","article-title":"STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis","volume":"60","author":"Dieud\u00e9 P","year":"2009","unstructured":"Dieud\u00e9 P, Guedj M, Wipff J, et al.. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 2009, 60:2472-9. 10.1002\/art.24688","journal-title":"Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215455","article-title":"Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre","volume":"78","author":"You H","year":"2019","unstructured":"You H, Zhang G, Wang Q, et al.. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019, 78:1441-3. 10.1136\/annrheumdis-2019-215455","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04956-7","article-title":"Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound","volume":"41","author":"Karalilova RV","year":"2021","unstructured":"Karalilova RV, Batalov ZA, Sapundzhieva TL, Matucci-Cerinic M, Batalov AZ. Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. Rheumatol Int. 2021, 41:1743-53. 10.1007\/s00296-021-04956-7","journal-title":"Rheumatol Int"},{"key":"ref9","article-title":"Pharmacological inhibition of JAK\/STAT signaling by tofacitinib prevents experimental organ fibrosis: novel therapy for systemic sclerosis (abstract)","volume":"70","author":"Bhattacharyya S","year":"2018","unstructured":"Bhattacharyya S, Wang W, Wei J, Varga J. Pharmacological inhibition of JAK\/STAT signaling by tofacitinib prevents experimental organ fibrosis: novel therapy for systemic sclerosis (abstract). Arthritis Rheumatol. 2018, 70:","journal-title":"Arthritis Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.34500","article-title":"JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis","volume":"64","author":"Dees C","year":"2012","unstructured":"Dees C, Tomcik M, Palumbo-Zerr K, et al.. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis. Arthritis Rheum. 2012, 64:3006-15. 10.1002\/art.34500","journal-title":"Arthritis Rheum"},{"key":"ref11","article-title":"Efficacy of tofacitinib in the treatment of early diffuse cutaneous systemic sclerosis: a clinical study in Bangladesh (abstract)","volume":"76","author":"Amin Z","year":"2024","unstructured":"Amin Z, Amin khan N, Shahin A, et al.. Efficacy of tofacitinib in the treatment of early diffuse cutaneous systemic sclerosis: a clinical study in Bangladesh (abstract). Arthritis Rheumatol. 2024, 76:","journal-title":"Arthritis Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen F","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al.. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013, 72:1747-55. 10.1136\/annrheumdis-2013-204424","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00765-9","article-title":"Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need","volume":"18","author":"Herrick AL","year":"2022","unstructured":"Herrick AL, Assassi S, Denton CP. Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. Nat Rev Rheumatol. 2022, 18:276-85. 10.1038\/s41584-022-00765-9","journal-title":"Nat Rev Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass AR","year":"2023","unstructured":"Bass AR, Chakravarty E, Akl EA, et al.. 2022 American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2023, 75:449-64. 10.1002\/acr.25045","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12032","article-title":"Cross-cultural adaptation and validation of a Bengali Health Assessment Questionnaire for use in rheumatoid arthritis patients","volume":"16","author":"Islam N","year":"2013","unstructured":"Islam N, Baron Basak T, OudeVoshaar MA, Ferdous N, Rasker JJ, Atiqul Haq S. Cross-cultural adaptation and validation of a Bengali Health Assessment Questionnaire for use in rheumatoid arthritis patients. Int J Rheum Dis. 2013, 16:413-7. 10.1111\/1756-185X.12032","journal-title":"Int J Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna D","year":"2017","unstructured":"Khanna D, Furst DE, Clements PJ, et al.. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017, 2:11-8. 10.5301\/jsrd.5000231","journal-title":"J Scleroderma Relat Disord"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/23971983251360883","article-title":"Clinical associations of worsening physical function as measured by HAQ-DI scores in systemic sclerosis","author":"Fairley JL","year":"2025","unstructured":"Fairley JL, Hansen D, Proudman S, et al.. Clinical associations of worsening physical function as measured by HAQ-DI scores in systemic sclerosis. J Scleroderma Relat Disord. 2025, 23971983251360883. 10.1177\/23971983251360883","journal-title":"J Scleroderma Relat Disord"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.4103\/2229-3485.71856","article-title":"Sample size estimation in clinical trial","volume":"1","author":"Sakpal TV","year":"2010","unstructured":"Sakpal TV. Sample size estimation in clinical trial. Perspect Clin Res. 2010, 1:67-9.","journal-title":"Perspect Clin Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3046.1999.00015.x","article-title":"Mycophenolate mofetil--is it worth the cost? The in-favor opinion","volume":"3","author":"Seikaly MG","year":"1999","unstructured":"Seikaly MG. Mycophenolate mofetil--is it worth the cost? The in-favor opinion. Pediatr Transplant. 1999, 3:79-82. 10.1034\/j.1399-3046.1999.00015.x","journal-title":"Pediatr Transplant"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210503","article-title":"Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)","volume":"76","author":"Herrick AL","year":"2017","unstructured":"Herrick AL, Pan X, Peytrignet S, et al.. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017, 76:1207-18. 10.1136\/annrheumdis-2016-210503","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_796_19","article-title":"Effect of monthly cyclophosphamide pulses on skin sclerosis in systemic sclerosis","volume":"87","author":"Khader A","year":"2021","unstructured":"Khader A, Valiaveetil B, Nalini SD, George B, Sasidharanpillai S, Nazeer MM, Manikath N. Effect of monthly cyclophosphamide pulses on skin sclerosis in systemic sclerosis. Indian J Dermatol Venereol Leprol. 2021, 87:728-31. 10.25259\/IJDVL_796_19","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa047","article-title":"Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis","volume":"59","author":"Kersten BE","year":"2020","unstructured":"Kersten BE, den Broeder N, van den Hoogen FH, Knaapen-Hans HA, van den Ende CH, Vonk MC. Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis. Rheumatology (Oxford). 2020, 59:1793. 10.1093\/rheumatology\/keaa047","journal-title":"Rheumatology (Oxford)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-3026-y","article-title":"Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study","volume":"34","author":"Poormoghim H","year":"2014","unstructured":"Poormoghim H, Rezaei N, Sheidaie Z, Almasi AR, Moradi-Lakeh M, Almasi S, Andalib E. Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study. Rheumatol Int. 2014, 34:1691-9. 10.1007\/s00296-014-3026-y","journal-title":"Rheumatol Int"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103439","article-title":"Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?","volume":"23","author":"Campochiaro C","year":"2024","unstructured":"Campochiaro C, Allanore Y, Braun-Moscovici Y, Matucci-Cerinic M, Balbir-Gurman A. Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?. Autoimmun Rev. 2024, 23:103439. 10.1016\/j.autrev.2023.103439","journal-title":"Autoimmun Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20136","article-title":"Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States","volume":"26","author":"Fan Y","year":"2020","unstructured":"Fan Y, Bender S, Shi W, Zoz D. Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States. J Manag Care Spec Pharm. 2020, 26:1539-47. 10.18553\/jmcp.2020.20136","journal-title":"J Manag Care Spec Pharm"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez322","article-title":"Enthesopathy and involvement of synovio-entheseal complex in systemic sclerosis: an ultrasound pilot study","volume":"59","author":"Terenzi R","year":"2020","unstructured":"Terenzi R, Karalilova R, Lepri G, et al.. Enthesopathy and involvement of synovio-entheseal complex in systemic sclerosis: an ultrasound pilot study. Rheumatology (Oxford). 2020, 59:580-5. 10.1093\/rheumatology\/kez322","journal-title":"Rheumatology (Oxford)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2828::aid-art470>3.0.co;2-u","article-title":"Improvement in skin thickening in systemic sclerosis associated with improved survival","volume":"44","author":"Steen VD","year":"2001","unstructured":"Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum. 2001, 44:2828-35. 10.1002\/1529-0131(200112)44:12&lt;2828::aid-art470&gt;3.0.co;2-u","journal-title":"Arthritis Rheum"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11125","article-title":"Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of scleroderma lung study II","volume":"2","author":"Volkmann ER","year":"2020","unstructured":"Volkmann ER, Tashkin DP, LeClair H, et al.. Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of scleroderma lung study II. ACR Open Rheumatol. 2020, 2:362-70. 10.1002\/acr2.11125","journal-title":"ACR Open Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/390701-efficacy-and-safety-of-tofacitinib-compared-to-cyclophosphamide-in-early-diffuse-cutaneous-systemic-sclerosis-a-randomized-controlled-trial","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:49:58Z","timestamp":1770479398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/390701-efficacy-and-safety-of-tofacitinib-compared-to-cyclophosphamide-in-early-diffuse-cutaneous-systemic-sclerosis-a-randomized-controlled-trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.103163","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,7]]}}}